2-Oxo-1-Pyrrolidinyl Triazole Derivatives for Cognitive Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cognitive disorders such as Alzheimer's disease and schizophrenia have limited efficacy and significant side effects, with a need for more effective medications to enhance cognitive function or counteract cognitive decline, especially in aging populations.
Innovation Solution
Development of 2-oxo-1-pyrrolidinyl triazole derivatives and their pharmaceutical compositions, which can be administered to improve cognitive function or counteract cognitive decline by enhancing neurotransmitter systems, specifically targeting cholinergic and glutamatergic pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current medications (cholinesterase inhibitors, memantine) are used to treat cognitive disorders, then some cognitive benefit is achieved, but side effects increase and efficacy remains limited
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of known active compounds (levetiracetam and piracetam) through systematic variation of substituents at specific positions (R1, R2, R3, R4, R5, R6) to optimize both efficacy and reduce side effects. This involves changing molecular weight, lipophilicity, and stereochemistry parameters to achieve improved therapeutic profiles
Solution Approach 2:
The patent employs composite materials by combining the pyrrolidinyl triazole core structure with various aromatic and aliphatic substituent groups to create a series of derivative compounds. These composite molecular structures leverage synergistic effects between different structural components to enhance cognitive efficacy while minimizing adverse effects
2Object-affected harmful factors
If levetiracetam is used as a protective agent for the central nervous system, then neuroprotection is provided, but cognitive function is not improved
Solution Approach 1:
The patent applies local quality by introducing specific functional groups and substituents at particular positions on the pyrrolidinyl triazole core structure. This localized modification of molecular properties enhances interaction with cognitive-related neurotransmitter systems while maintaining the neuroprotective characteristics of the parent compound
Solution Approach 2:
The patent employs dynamics by creating enantiomeric forms and stereoisomers with different spatial configurations. The (R)- and (S)-enantiomers exhibit different biological activities, allowing optimization of cognitive enhancement while maintaining neuroprotection through selective stereochemical configuration
3Duration of action of stationary object
If the population lifespan increases and aging occurs, then more time is available, but cognitive function naturally declines
Solution Approach 1:
The patent applies preliminary action by developing compounds that can prevent or delay cognitive decline before it becomes severe. The pyrrolidinyl triazole derivatives are designed to proactively protect cognitive function through enhanced neuroprotection and neurotransmitter modulation, allowing intervention at early stages of aging or cognitive impairment
Solution Approach 2:
The patent employs continuity of useful action by creating compounds with sustained activity in the central nervous system. The molecular structures are optimized for prolonged interaction with target receptors and neurotransmitter systems, providing continuous cognitive enhancement and protection throughout the dosing interval and over extended treatment periods
Data Source
AI summary
The invention relates to 2-oxo-1-pyrrolidinyl triazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals for enhancing the cognitive function or to counteract cognitive decline.